Silence Therapeutics plc (SLN) Ordinary 5p
Share news, reports & tips
26 February 2021 09:06
(Sharecast News) - Silence Therapeutics announced on Friday that it would receive a $2m (£1.43m) milestone payment following the start of work on a third target being explored under its ongoing RNAi...
17 February 2021 08:12
(Sharecast News) - Silence Therapeutics has started dosing subjects in the 'APOLLO' phase 1 clinical study of its wholly-owned lead product candidate 'SLN360', it announced on Wednesday,...
5 February 2021 09:04
(Sharecast News) - Novel therapeutics developer Silence Therapeutics announced an oversubscribed private placement of 2,022,218 American depositary shares (ADSs) on Friday, raising £33m to support the...
6 January 2021 08:06
(Sharecast News) - Drug discovery outfit Silence Therapeutics has named Craig Tooman as its new chief financial officer.
14 September 2020 13:14
(Sharecast News) - Drug discovery and development company Silence Therapeutics announced the appointment of Mark Rothera as its president and chief executive officer and board member on Monday, effective...
16 July 2020 12:33
(Sharecast News) - Silence Therapeutics announced on Thursday that Mallinckrodt has exercised its option, under the collaboration agreement announced in July 2019, to obtain exclusive worldwide licences for...
23 June 2020 10:14
(Sharecast News) - RNA therapeutics developer Silence Therapeutics said on Tuesday that it had continued to make "exceptional progress" in securing additional high-value partnerships and advancing...
12 May 2020 15:45
(Sharecast News) - Silence Therapeutics revealed on Tuesday that chief financial officer Rob Quinn had offloaded of 89,054 ordinary shares in the AIM-listed biotechnology group.
7 January 2020 15:43
(Sharecast News) - Serious disease therapeutics developer Silence Therapeutics updated the market on the year ended 31 December on Tuesday, reporting that it has entered into a technology evaluation...
17 December 2019 13:50
(Sharecast News) - Silence Therapeutics announced a "strengthening" of its board and management team on Tuesday, with Iain Ross set to be appointed as executive chairman from 1 January.
12 September 2019 09:15
(Sharecast News) - Silence Therapeutics said on Thursday that the first half of the year saw good progress in the development of its lead candidate, SLN124, with the first patient set to be dosed before the...
5 August 2019 11:52
(Sharecast News) - Silence Therapeutics announced on Monday that Jørgen Wittendorff has been appointed to the new role of its head of manufacturing.
Company announcements Announcements
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2021. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.